

John Kanellis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3711614/publications.pdf>

Version: 2024-02-01

130
papers

7,737
citations

94269

37
h-index

51492

86
g-index

130
all docs

130
docs citations

130
times ranked

8818
citing authors

#	ARTICLE	IF	CITATIONS
1	Is There a Pathogenetic Role for Uric Acid in Hypertension and Cardiovascular and Renal Disease?. Hypertension, 2003, 41, 1183-1190.	1.3	1,121
2	Uric Acid Stimulates Monocyte Chemoattractant Protein-1 Production in Vascular Smooth Muscle Cells Via Mitogen-Activated Protein Kinase and Cyclooxygenase-2. Hypertension, 2003, 41, 1287-1293.	1.3	695
3	Hyperuricemia induces a primary renal arteriopathy in rats by a blood pressure-independent mechanism. American Journal of Physiology - Renal Physiology, 2002, 282, F991-F997.	1.3	682
4	Uric Acid, Hominoid Evolution, and the Pathogenesis of Salt-Sensitivity. Hypertension, 2002, 40, 355-360.	1.3	478
5	Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease. Seminars in Nephrology, 2005, 25, 39-42.	0.6	350
6	Role of the Microvascular Endothelium in Progressive Renal Disease. Journal of the American Society of Nephrology: JASN, 2002, 13, 806-816.	3.0	301
7	Effects of Allopurinol on the Progression of Chronic Kidney Disease. New England Journal of Medicine, 2020, 382, 2504-2513.	13.9	281
8	Decreased allergic lung inflammatory cell egression and increased susceptibility to asphyxiation in MMP2-deficiency. Nature Immunology, 2002, 3, 347-353.	7.0	244
9	Hyperuricemia Causes Glomerular Hypertrophy in the Rat. American Journal of Nephrology, 2003, 23, 2-7.	1.4	224
10	Uric Acid Causes Vascular Smooth Muscle Cell Proliferation by Entering Cells via a Functional Urate Transporter. American Journal of Nephrology, 2005, 25, 425-433.	1.4	215
11	Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrology Dialysis Transplantation, 2014, 29, 406-413.	0.4	191
12	Serum Uric Acid: A Risk Factor and a Target for Treatment?. Journal of the American Society of Nephrology: JASN, 2006, 17, S69-S73.	3.0	135
13	The Motivations and Experiences of Living Kidney Donors: A Thematic Synthesis. American Journal of Kidney Diseases, 2012, 60, 15-26.	2.1	123
14	A Systematic Review of Conversion From Calcineurin Inhibitor to Mammalian Target of Rapamycin Inhibitors for Maintenance Immunosuppression in Kidney Transplant Recipients. American Journal of Transplantation, 2014, 14, 2106-2119.	2.6	123
15	Vascular endothelial growth factor is a survival factor for renal tubular epithelial cells. American Journal of Physiology - Renal Physiology, 2000, 278, F905-F915.	1.3	106
16	Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: A randomized trial. American Journal of Transplantation, 2019, 19, 2876-2888.	2.6	95
17	Uric acid, endothelial dysfunction and pre-eclampsia. Journal of Hypertension, 2004, 22, 229-235.	0.3	84
18	Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial. American Journal of Kidney Diseases, 2016, 67, 648-659.	2.1	78

#	ARTICLE	IF	CITATIONS
19	Understanding crossmatch testing in organ transplantation: A case-based guide for the general nephrologist. <i>Nephrology</i> , 2011, 16, 125-133.	0.7	77
20	Diagnostic application of kidney allograft-derived absolute cell-free DNA levels during transplant dysfunction. <i>American Journal of Transplantation</i> , 2019, 19, 1037-1049.	2.6	71
21	A Single Low-Fixed Dose of Rituximab to Salvage Renal Transplants From Refractory Antibody-Mediated Rejection. <i>Transplantation</i> , 2009, 87, 286-289.	0.5	68
22	Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial. <i>American Journal of Transplantation</i> , 2017, 17, 1853-1867.	2.6	68
23	Developing Consensus-Based Priority Outcome Domains for Trials in Kidney Transplantation. <i>Transplantation</i> , 2017, 101, 1875-1886.	0.5	68
24	Stanniocalcin-1, an inhibitor of macrophage chemotaxis and chemokinesis. <i>American Journal of Physiology - Renal Physiology</i> , 2004, 286, F356-F362.	1.3	64
25	Increased expression of heparanase in puromycin aminonucleoside nephrosis. <i>Kidney International</i> , 2001, 60, 1287-1296.	2.6	61
26	Mycophenolate and lower graft function reduce the seroresponse of kidney transplant recipients to pandemic H1N1 vaccination. <i>Kidney International</i> , 2012, 82, 212-219.	2.6	60
27	Does asymptomatic hyperuricaemia contribute to the development of renal and cardiovascular disease? An old controversy renewed. <i>Nephrology</i> , 2004, 9, 394-399.	0.7	59
28	Redistribution of cytoplasmic VEGF to the basolateral aspect of renal tubular cells in ischemia-reperfusion injury. <i>Kidney International</i> , 2000, 57, 2445-2456.	2.6	56
29	KHA-CARI guideline: KHA-CARI adaptation of the KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. <i>Nephrology</i> , 2012, 17, 204-214.	0.7	56
30	Modulation of Inflammation by Slit Protein In Vivo in Experimental Crescentic Glomerulonephritis. <i>American Journal of Pathology</i> , 2004, 165, 341-352.	1.9	54
31	Renal ischemia-reperfusion increases endothelial VEGFR-2 without increasing VEGF or VEGFR-1 expression. <i>Kidney International</i> , 2002, 61, 1696-1706.	2.6	49
32	Renal Transplant Patients at High Risk of Acute Rejection Benefit From Adequate Exposure to Mycophenolic Acid. <i>Transplantation</i> , 2010, 89, 595-599.	0.5	48
33	Challenges of conducting a trial of uric-acid-lowering therapy in CKD. <i>Nature Reviews Nephrology</i> , 2011, 7, 295-300.	4.1	46
34	Long-term outcomes of end-stage kidney disease for patients with lupus nephritis. <i>Kidney International</i> , 2016, 89, 1337-1345.	2.6	44
35	The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine. <i>Kidney International</i> , 2017, 91, 954-963.	2.6	44
36	JNK signalling in human and experimental renal ischaemia/reperfusion injury. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 2898-2908.	0.4	42

#	ARTICLE	IF	CITATIONS
37	Systemic inflammation, metabolic syndrome and progressive renal disease. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 1384-1387.	0.4	41
38	A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in <i>de novo</i> kidney transplant recipients. <i>Transplant International</i> , 2014, 27, 302-311.	0.8	39
39	Justification for living donor kidney transplantation. <i>Nephrology</i> , 2010, 15, S72-9.	0.7	38
40	Inhibition of p38 Mitogen-Activated Protein Kinase Augments Progression of Remnant Kidney Model by Activating the ERK Pathway. <i>American Journal of Pathology</i> , 2004, 164, 477-485.	1.9	37
41	Identifying Outcomes that Are Important to Living Kidney Donors. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 916-926.	2.2	35
42	Allocation of deceased donor kidneys: A review of international practices. <i>Nephrology</i> , 2019, 24, 591-598.	0.7	31
43	Heparin-binding epidermal growth factor-like growth factor in experimental models of membranous and minimal change nephropathy. <i>Kidney International</i> , 1998, 53, 1162-1171.	2.6	29
44	Editorial Comment—Elevated Uric Acid and Ischemic Stroke: Accumulating Evidence That It Is Injurious and Not Neuroprotective. <i>Stroke</i> , 2003, 34, 1956-1957.	1.0	29
45	Slow and steady. Reducing thrombotic events in renal transplant recipients treated with IVIg for antibody-mediated rejection. <i>Nephrology</i> , 2011, 16, 239-242.	0.7	28
46	Donor and Recipient Views on Their Relationship in Living Kidney Donation: Thematic Synthesis of Qualitative Studies. <i>American Journal of Kidney Diseases</i> , 2017, 69, 602-616.	2.1	28
47	Establishing a Core Outcome Measure for Life Participation: A Standardized Outcomes in Nephrology-kidney Transplantation Consensus Workshop Report. <i>Transplantation</i> , 2019, 103, 1199-1205.	0.5	26
48	Donor renal function. <i>Nephrology</i> , 2010, 15, S137-45.	0.7	25
49	Spleen tyrosine kinase promotes acute neutrophil-mediated glomerular injury via activation of JNK and p38 MAPK in rat nephrotoxic serum nephritis. <i>Laboratory Investigation</i> , 2011, 91, 1727-1738.	1.7	25
50	Macrophages Contribute to Cellular But Not Humoral Mechanisms of Acute Rejection in Rat Renal Allografts. <i>Transplantation</i> , 2013, 96, 949-957.	0.5	25
51	The Lived Experience of "Being Evaluated" for Organ Donation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1852-1861.	2.2	25
52	Access to waitlisting for deceased donor kidney transplantation in Australia. <i>Nephrology</i> , 2019, 24, 758-766.	0.7	25
53	Untapped potential in Australian hospitals for organ donation after circulatory death. <i>Medical Journal of Australia</i> , 2017, 207, 294-301.	0.8	24
54	External validation of the US and UK kidney donor risk indices for deceased donor kidney transplant survival in the Australian and New Zealand population. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 2127-2131.	0.4	24

#	ARTICLE	IF	CITATIONS
55	Heparin-binding epidermal growth factor-like growth factor is expressed in the adhesive lesions of experimental focal glomerular sclerosis. <i>Kidney International</i> , 1999, 55, 2310-2321.	2.6	23
56	A Single Pathway for the Development of Essential Hypertension. <i>Cardiology in Review</i> , 2003, 11, 180-196.	0.6	23
57	International travel in the immunocompromised patient: a cross-sectional survey of travel advice in 254 consecutive patients. <i>Internal Medicine Journal</i> , 2015, 45, 618-623.	0.5	23
58	Cardiovascular Parameters to 2 years After Kidney Transplantation Following Early Switch to Everolimus Without Calcineurin Inhibitor Therapy. <i>Transplantation</i> , 2017, 101, 2612-2620.	0.5	23
59	Early pancreas allograft thrombosis. <i>Clinical Transplantation</i> , 2013, 27, 410-416.	0.8	22
60	Seroresponses and safety of 13-valent pneumococcal conjugate vaccination in kidney transplant recipients. <i>Transplant Infectious Disease</i> , 2018, 20, e12866.	0.7	22
61	Activators of the energy sensing kinase AMPK inhibit random cell movement and chemotaxis in U937 cells. <i>Immunology and Cell Biology</i> , 2006, 84, 6-12.	1.0	21
62	Suspension and resumption of kidney transplant programmes during the COVID-19 pandemic: perspectives from patients, caregivers and potential living donors – a qualitative study. <i>Transplant International</i> , 2020, 33, 1481-1490.	0.8	21
63	Spleen Tyrosine Kinase Signaling Promotes Myeloid Cell Recruitment and Kidney Damage after Renal Ischemia/Reperfusion Injury. <i>American Journal of Pathology</i> , 2016, 186, 2032-2042.	1.9	20
64	Natural killer cell function predicts severe infection in kidney transplant recipients. <i>American Journal of Transplantation</i> , 2019, 19, 166-177.	2.6	20
65	Myeloid cell-mediated renal injury in rapidly progressive glomerulonephritis depends upon spleen tyrosine kinase. <i>Journal of Pathology</i> , 2016, 238, 10-20.	2.1	19
66	Donors at risk: hypertension. <i>Nephrology</i> , 2010, 15, S114-20.	0.7	18
67	Cyclophilin A Promotes Inflammation in Acute Kidney Injury but Not in Renal Fibrosis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3667.	1.8	18
68	Cyclophilin Inhibition Protects Against Experimental Acute Kidney Injury and Renal Interstitial Fibrosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 271.	1.8	17
69	A Study of VEGF and Its Receptors in Two Rat Models of Proteinuria. <i>Nephron Physiology</i> , 2004, 96, p26-p36.	1.5	16
70	Kidney transplant recipient perspectives on telehealth during the COVID-19 pandemic. <i>Transplant International</i> , 2021, 34, 1517-1529.	0.8	16
71	Thin Basement Membrane Nephropathy and Renal Transplantation. <i>Seminars in Nephrology</i> , 2005, 25, 184-187.	0.6	15
72	Factors associated with anaemia in kidney transplant recipients in the first year after transplantation: a cross-sectional study. <i>BMC Nephrology</i> , 2018, 19, 252.	0.8	15

#	ARTICLE	IF	CITATIONS
73	De novo or early conversion to everolimus and long-term cancer outcomes in kidney transplant recipients: A trial-based linkage study. <i>American Journal of Transplantation</i> , 2018, 18, 2977-2986.	2.6	15
74	Reducing uric acid as a means to prevent cardiovascular and renal disease. <i>Expert Opinion on Therapeutic Patents</i> , 2002, 12, 193-199.	2.4	13
75	Epstein-Barr virus encephalitis in solid organ transplantation. <i>New Microbiologica</i> , 2017, 40, 212-217.	0.1	13
76	Managing psychosis in a renal transplant recipient with bipolar affective disorder and allograft rejection. <i>Nephrology</i> , 2015, 20, 2-5.	0.7	12
77	De novo thrombotic microangiopathy following simultaneous pancreas and kidney transplantation managed with eculizumab. <i>Nephrology</i> , 2017, 22, 23-27.	0.7	12
78	Expectations and Experiences of Follow-up and Self-Care After Living Kidney Donation. <i>Transplantation</i> , 2017, 101, 2627-2635.	0.5	12
79	The experiences and impact of being deemed ineligible for living kidney donation: Semi-structured interview study. <i>Nephrology</i> , 2020, 25, 339-350.	0.7	12
80	Long-term graft survival in patients with chronic antibody-mediated rejection with persistent peritubular capillaritis treated with intravenous immunoglobulin and rituximab. <i>Clinical Transplantation</i> , 2017, 31, e13037.	0.8	11
81	Skin cancer history, sun-related attitudes, behaviour and sunburn among renal transplant recipients versus general population. <i>Australasian Journal of Dermatology</i> , 2018, 59, e106-e113.	0.4	11
82	Inhibition of Spleen Tyrosine Kinase Reduces Renal Allograft Injury in a Rat Model of Acute Antibody-Mediated Rejection in Sensitized Recipients. <i>Transplantation</i> , 2017, 101, e240-e248.	0.5	10
83	Kidney donation and transplantation in Australia: more than a supply and demand equation. <i>Medical Journal of Australia</i> , 2018, 209, 242-243.	0.8	9
84	Initial mycophenolate dose in tacrolimus treated renal transplant recipients, a cohort study comparing leukopaenia, rejection and long-term graft function. <i>Scientific Reports</i> , 2020, 10, 19379.	1.6	9
85	Different faces of <i>Nocardia</i> infection in renal transplant recipients. <i>Nephrology</i> , 2016, 21, 254-260.	0.7	8
86	Long-term outcomes of end-stage kidney disease for patients with <i>IgA</i> nephropathy: A multi-centre registry study. <i>Nephrology</i> , 2016, 21, 387-396.	0.7	8
87	Direct and indirect costs incurred by Australian living kidney donors. <i>Nephrology</i> , 2018, 23, 1145-1151.	0.7	8
88	Survival and Quality of Life Impact of a Risk-based Allocation Algorithm for Deceased Donor Kidney Transplantation. <i>Transplantation</i> , 2018, 102, 1530-1537.	0.5	8
89	Confirmed microsporidial graft infection in a <i>HIV</i> -negative renal transplant recipient: A case report and review of the literature. <i>Transplant Infectious Disease</i> , 2018, 20, e12888.	0.7	8
90	Donors at risk: proteinuria. <i>Nephrology</i> , 2010, 15, S106-10.	0.7	7

#	ARTICLE	IF	CITATIONS
91	Renal transplant ultrasound: The nephrologist's perspective. <i>Australasian Journal of Ultrasound in Medicine</i> , 2015, 18, 134-142.	0.3	7
92	Spleen tyrosine kinase contributes to acute renal allograft rejection in the rat. <i>International Journal of Experimental Pathology</i> , 2015, 96, 54-62.	0.6	7
93	Methods in renal research: kidney transplantation in the rat. <i>Nephrology</i> , 2016, 21, 451-456.	0.7	7
94	A simple score can identify kidney transplant recipients at high risk of severe infection over the following 2 years. <i>Transplant Infectious Disease</i> , 2019, 21, e13076.	0.7	6
95	Clinicians' attitudes and approaches to evaluating the potential living kidney donor-recipient relationship: An interview study. <i>Nephrology</i> , 2019, 24, 252-262.	0.7	6
96	Donors at risk: haematuria. <i>Nephrology</i> , 2010, 15, S111-3.	0.7	5
97	Recurrent glomerulopathy in a renal allograft due to lecithin cholesterol acyltransferase deficiency. <i>Nephrology</i> , 2016, 21, 73-74.	0.7	5
98	Risk Indices in Deceased-donor Organ Allocation for Transplantation: Review From an Australian Perspective. <i>Transplantation</i> , 2019, 103, 875-889.	0.5	5
99	Pregnancy outcomes for simultaneous Pancreas-Kidney transplant recipients versus kidney transplant recipients. <i>Clinical Transplantation</i> , 2021, 35, e14151.	0.8	5
100	Cyclophilin D Promotes Acute, but Not Chronic, Kidney Injury in a Mouse Model of Aristolochic Acid Toxicity. <i>Toxins</i> , 2021, 13, 700.	1.5	5
101	Initial Australasian experience with portal-enteric drainage in simultaneous pancreas-kidney transplantation. <i>ANZ Journal of Surgery</i> , 2010, 80, 722-727.	0.3	4
102	Living donor transplantation: is there inequality of access?. <i>ANZ Journal of Surgery</i> , 2011, 81, 2-3.	0.3	4
103	Everolimus and Long-term Clinical Outcomes in Kidney Transplant Recipients: A Registry-based 10-year Follow-up of 5 Randomized Trials. <i>Transplantation</i> , 2019, 103, 1705-1713.	0.5	4
104	BK virus RNA can be detected in archival renal transplant biopsies using the reverse transcription polymerase chain reaction. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 661-666.	0.4	3
105	GLOMERULAR LIPID DEPOSITION: A CLUE TO ILLICIT INTRAVENOUS DRUG USE. <i>Nephrology</i> , 2009, 14, 358-359.	0.7	3
106	Laboratory Identification of Donor-Derived Coxsackievirus B3 Transmission. <i>American Journal of Transplantation</i> , 2015, 15, 555-559.	2.6	3
107	Frequency and outcomes of kidney donation from intensive care patients with acute renal failure requiring renal replacement therapy. <i>Nephrology</i> , 2019, 24, 1296-1303.	0.7	3
108	Insights into the labeling effect of Kidney Donor Performance Index reporting: The Australian experience. <i>American Journal of Transplantation</i> , 2020, 20, 870-878.	2.6	3

#	ARTICLE	IF	CITATIONS
109	Jurisdictional inequalities in deceased donor kidney allocation in Australia. <i>Kidney International</i> , 2021, 100, 49-54.	2.6	3
110	A Model of Acute Antibody-Mediated Renal Allograft Rejection in the Sensitized Rata. <i>Experimental and Clinical Transplantation</i> , 2018, 16, 294-300.	0.2	3
111	Primary central nervous system posttransplant lymphoproliferative disease: An uncommon diagnostic dilemma. <i>Nephrology</i> , 2016, 21, 528-528.	0.7	2
112	Occupational <sc><i>Legionella pneumophila</i></sc> Exposure in a Street Sweeper with a Renal Transplant. <i>Nephrology</i> , 2018, 23, 493-494.	0.7	2
113	KHAâ€CARI commentary on the KDIGO clinical practice guideline on the evaluation and care of living kidney donors. <i>Nephrology</i> , 2020, 25, 96-98.	0.7	2
114	Implementation and learning of laproscopic donor nephrectomy by a non-transplant general surgeon with advanced laparoscopic skills. <i>Asian Journal of Endoscopic Surgery</i> , 2011, 4, 127-132.	0.4	1
115	Transplant considerations in a man with von Hippel-Lindau disease with bilateral renal cell carcinoma and a pancreatic neuroendocrine tumour. <i>Nephrology</i> , 2015, 20, 956-957.	0.7	1
116	Transplant Professionalsâ€™ Attitudes and Approaches to the Living Kidney Donor-Recipient Relationship. <i>Transplantation</i> , 2017, 101, S94.	0.5	1
117	Measurement of Humoral Immune Competence and the Risk of Sinopulmonary Infection in a Cohort of Kidney Transplant Recipients. <i>Transplantation Proceedings</i> , 2018, 50, 3367-3370.	0.3	1
118	Factors Associated with Time to Deceased Donor Renal Transplant Waitlisting or Living Donor Transplantation in Australia. <i>Transplantation</i> , 2018, 102, S576.	0.5	1
119	Risk indices predicting graft use, graft and patient survival in solid pancreas transplantation: a systematic review. <i>BMC Gastroenterology</i> , 2021, 21, 80.	0.8	1
120	Results from an International Survey of Donor and Recipient Eligibility for Solid Organ Pancreas Transplantation. <i>Annals of Transplantation</i> , 2021, 26, e930787.	0.5	1
121	Upregulation of heparinâ€binding epidermal growth factorâ€like growth factor and osteopontin in experimental hydronephrosis. <i>Nephrology</i> , 2000, 5, 201-208.	0.7	0
122	Rituximab for Antibody-Mediated Rejection, Less May Be More. <i>Transplantation</i> , 2009, 88, 142-143.	0.5	0
123	Evaluation and Preoperative Management of Kidney Transplant Recipient and Donor. , 2010, , 1142-1153.		0
124	ALLOCATING THE UNEXPECTED KIDNEY. <i>Nephrology</i> , 2012, 17, 588-589.	0.7	0
125	The Lived Experience of â€Being Evaluatedâ€™ for Organ Donation. <i>Transplantation</i> , 2017, 101, S72.	0.5	0
126	De Novo or Early Conversion to Everolimus and Cancer Incidence in Kidney Transplant Recipients. <i>Transplantation</i> , 2018, 102, S343.	0.5	0

#	ARTICLE	IF	CITATIONS
127	Recurrent membranoproliferative glomerulonephritis in a renal transplant secondary to monoclonal gammopathy of renal significance successfully treated with bortezomib. Internal Medicine Journal, 2019, 49, 801-802.	0.5	0
128	Long-Term Graft and Patient Outcomes Following Kidney Transplantation in End-Stage Kidney Disease Secondary to Hyperoxaluria. Transplantation Proceedings, 2021, 53, 839-847.	0.3	0
129	Successful Implementation of an Increased Viral Risk Donor Waiting List for Preconsented Kidney Transplant Candidates in Victoria, Australia. Transplantation Direct, 2021, 7, e758.	0.8	0
130	Donor Predictors of Donor Pancreas Retrieval and Subsequent Solid Pancreas Transplantation in Australia and New Zealand from 2007 to 2016. Transplantation Proceedings, 2021, 53, 2358-2368.	0.3	0